Results 81 to 90 of about 2,244 (146)

Thyroid and renal tumors in patients treated with long-term lithium: case series from a lithium clinic, review of the literature and international pharmacovigilance reports

open access: yesInternational Journal of Bipolar Disorders, 2018
Background Cancer had never been considered as a relevant problem in patients treated with lithium until 2015, when a document published by the European Medicine Agency concluded that long-term use of lithium might induce renal tumors. A few months later,
Luca Ambrosiani   +5 more
doaj   +1 more source

Reported cutaneous allergies to antimicrobials in EudraVigilance

open access: yes
The thesis is a retrospective analysis of cutaneous adverse drug reactions that occurred after taking antibiotics, with a study period that covers a 10-year period from 2013 to 2023.
Chiwara, Tonderai Asher
core  

Analysis of adverse events of anaplastic lymphoma kinase inhibitors reported in the pharmacovigilance database EudraVigilance

open access: yes
Preden je zdravilo odobreno za uporabo, so dokazi o njegovi varnosti in učinkovitosti omejeni na klinična preskušanja. Po pridobitvi dovoljenja za promet se zdravilo lahko uporablja pri večjem številu bolnikov, dalj časa in skupaj z drugimi zdravili.
Šukalo, Nataša
core  

Age-Dependent Analysis of Suicidal Ideation, Suicide Attempts, and Suicides Associated with SSRI and SNRI Drugs Based on Pharmacovigilance Data

open access: yesPharmaceuticals
Background: Antidepressants such as SSRIs and SNRIs are widely prescribed; however, significant concerns exist regarding psychiatric adverse drug reactions (ADRs), particularly suicidal ideation, suicide attempts, and completed suicides.
Daria Schetz   +3 more
doaj   +1 more source

Comparison of injective related reactions following ofatumumab and ocrelizumab in patients with multiple sclerosis: data from the European spontaneous reporting system

open access: yesFrontiers in Neurology
IntroductionIn 2021 ofatumumab, a recombinant human anti-CD20 monoclonal antibody (mAb) already authorized for the treatment of chronic lymphocytic leukemia, received the marketing approval for the treatment of relapsing forms of multiple sclerosis (MS).
Cristina Scavone   +17 more
doaj   +1 more source

Safety Profile and Suicidality Associated with the Use of Esketamine in the Treatment of Major Depressive Disorder in European Countries: An EudraVigilance Database Analysis

open access: yesPharmaceuticals
Background/Objective: Major depressive disorder (MDD) is a common mental disorder, with a significant portion of patients developing treatment-resistant depression (TRD).
Ilaria Ammendolia   +8 more
doaj   +1 more source

Publication Only

open access: yes
HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

Adverse events of acute nephrotoxicity reported to EudraVigilance and VAERS after COVID-19 vaccination

open access: yes, 2023
Objectives: The present study aimed to estimate the reporting rates (RRs) of acute kidney injury (AKI) and renal failure (RF) after COVID-19 vaccination in the European Economic Area (EEA) and the United States.
Vasileiou, Konstantinos   +5 more
core  

Risk Management of Medication Errors: Improving the Quality of Pharmacotherapeutic Practice

open access: yesPharmacology Research & Perspectives
A key challenge when identifying opportunities and prioritizing strategies for quality improvement of healthcare services is an accurate design specification against which clinical performance can be assessed.
Richard Anthony Despott   +2 more
doaj   +1 more source

Open-Access Adverse Drug Reaction Databases: Applicability for Safety Assessment of the Developed Drugs (Review)

open access: yesБезопасность и риск фармакотерапии
INTRODUCTION. Evaluating safety data on already registered drugs is an important stage in medicine development. Databases (DBs) of adverse drug reactions (ADRs) have been created and maintained by regulatory authorities and individual research groups ...
P. I. Savosina   +2 more
doaj   +1 more source

Home - About - Disclaimer - Privacy